España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Anthera Pharmaceuticals
ANTH
OTCEM
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
Get Report
Comment
Anthera Pharmaceuticals (ANTH) Forecast
News
Earnings
Anthera Pharmaceuticals (ANTH) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Anthera Pharmaceuticals (OTC:ANTH) Stock
Anthera Pharmaceuticals Stock (OTC: ANTH)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, November 05, 2020
'Trading Nation' Analysts Give Their Health Care Picks
Craig Jones
Tuesday, March 24, 2020
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
Stocks That Hit 52-Week Highs On Tuesday
Benzinga Insights
Friday, December 13, 2019
Stocks That Hit 52-Week Lows On Friday
Lisa Levin
Wednesday, January 30, 2019
Anthem Raises Quarterly Dividend From $0.75 T...
Benzinga Newsdesk
Thursday, June 28, 2018
Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut
Benzinga
Wednesday, June 27, 2018
Anthera Pharma Reports Withdrawal Of Nasdaq's...
Benzinga
Friday, May 25, 2018
Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended
Benzinga
Friday, May 18, 2018
Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved
Benzinga
Thursday, May 17, 2018
Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More
Benzinga
Monday, April 16, 2018
UPDATE: Anthera Pharma Says Plans To Eliminat...
Benzinga
Anthera Pharma 8-K Shows Board Approved, Comm...
Benzinga
Monday, March 26, 2018
17 Stocks Moving In Monday's Pre-Market Session
Benzinga
Friday, March 16, 2018
The Week Ahead In Biotech: Earnings, PDUFA Dates And More
Benzinga
Tuesday, March 13, 2018
Benzinga Pro's Top 10 Most-Searched Tickers On Tues., Mar. 13
Benzinga
46 Biggest Movers From Yesterday
Benzinga
Monday, March 12, 2018
Mid-Afternoon Market Update: BlueLinx Surges On Cedar Creek Acquisition; Anthera Pharmaceuticals Shares Plunge
Benzinga
32 Stocks Moving In Monday's Mid-Day Session
Benzinga
Mid-Day Market Update: Dow Turns Negative; United Community Bancorp Shares Spike Higher
Benzinga
Mid-Morning Market Update: Markets Open Higher; Lumentum To Acquire Oclaro For $9.99/Share
Benzinga
Anthera Pharmaceuticals Shares Down 81.9% Fol...
Benzinga
Anthera Pharma's Phase 3 Study of Sollpura Di...
Benzinga
Anthera Phamra Halted, News Pending
Benzinga
Tuesday, March 06, 2018
Anthera Pharma S-3 Shows Registration For $10...
Benzinga
Monday, March 05, 2018
Anthera Pharmaceuticals Reports Q4 EPS $(0.73...
Benzinga
Thursday, February 22, 2018
41 Biggest Movers From Yesterday
Benzinga
Wednesday, February 21, 2018
Mid-Afternoon Market Update: Hackett Group Rises On Upbeat Earnings; QTS Realty Trust Shares Plunge
Benzinga
34 Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Mid-Day Market Update: Dow Gains Over 100 Points; Tile Shop Shares Fall On Earnings Miss
Benzinga
Anthera Pharmaceuticals Shares Up 37.3% As Ro...
Benzinga
Benzinga's Top Upgrades, Downgrades For February 21, 2018
Benzinga
Roth Capital Initiates Coverage On Anthera Pharmaceuticals with Buy Rating, Announces $10.00 Price Target
Benzinga
Thursday, February 15, 2018
22 Stocks Moving In Thursday's Pre-Market Session
Benzinga
Monday, February 05, 2018
Anthera Concludes Last Patient Visit in the Phase 3 RESULT Clinical Study of Sollpura
Benzinga
Monday, January 22, 2018
Anthera Announces a 'Positive' Outcome of Sec...
Benzinga
Monday, December 11, 2017
Anthera Pharma Offers Outcome Of Interim Futi...
Benzinga
Tuesday, November 21, 2017
35 Biggest Movers From Yesterday
Benzinga
Monday, November 20, 2017
34 Stocks Moving In Monday's Mid-Day Session
Benzinga
Monday, November 13, 2017
Anthera Pharmaceuticals Files For $50,073,580...
Benzinga
Monday, November 06, 2017
Anthera Pharmaceuticals Reports Q3 EPS $(0.58...
Benzinga
Tuesday, October 24, 2017
35 Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Anthera Pharma Prices ~2.307M Share Offering ...
Benzinga
Thursday, September 07, 2017
Anthera Pharma Reports Surpassed 50% Mileston...
Benzinga
Monday, August 28, 2017
Anthera Reports Top Line Final Data from the Extension Period of the Phase 2 BRIGHT-SC Study
Benzinga
Monday, August 14, 2017
Anthera Pharma Reports RESULT Phase 3 Study O...
Benzinga
Wednesday, August 09, 2017
Anthera Reports FDA Orphan Drug Designation F...
Benzinga
Anthera Pharma Reports Q2 EPS $0.03 vs $(2.79...
Benzinga
Monday, July 10, 2017
Anthera Pharmaceuticals Reports Phase 3 Sollp...
Benzinga
Thursday, July 06, 2017
Anthera Reports Expansion of Screening in Eur...
Benzinga
Monday, May 15, 2017
Anthera Announces 1st Patient Screened In RESULT Pivotal Phase 3 Sollpura Study
Benzinga
Show More